In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...

A key advantage of using RWD in a natural history study is gaining diverse and representative data. RWD covers broad patient populations, including those with comorbidities, various age groups, and ...

Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...

Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...

Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...

Novo Nordisk partners with Vivtex Corporation to develop next-generation oral biologics for obesity and diabetes, while GSK ...

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry ...

This episode of The Ron Lanton Report examines whether healthcare consolidation in the United States may be approaching a ...

PE: What is the reaction to DTC pharma advertising? Donaldson: Consumers will slowly but surely have increased distrust in ...

Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.